Germany’s BioNTech buys China’s Biotheus in US$800 million push into cancer drugs

Q: How long will it take to read this news story?

The story "Germany’s BioNTech buys China’s Biotheus in US$800 million push into cancer drugs" has 251 words across 7 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Germany’s BioNTech buys China’s Biotheus in US$800 million push into cancer drugs" was covered 5 days ago by SCMP, a news publisher based in Hong Kong.

Q: How trustworthy is 'SCMP' news outlet?

SCMP is a fully independent (privately-owned) news outlet established in 1903 that covers mostly business news. The outlet is headquartered in Hong Kong and publishes an average of 19 news stories per day. It's most recent story was published 35 minutes ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23685079</li><li>URL: https://beamstart.com/news/germanys-biontech-buys-chinas-biotheus-17319822591</li></ul>

SCMP Logo SCMP 5d ago

Germany’s BioNTech buys China’s Biotheus in US$800 million push into cancer drugs - SCMP

Quick Summary:

BioNTech says deal will support its push into the development of cancer drugs using its proven mRNA technology.

China, the world’s second largest pharmaceutical market after the US, was estimated to have had about 4.82 million new cancer cases and 2.57 million cancer deaths in 2022, according to a paper published in March by researchers at the National Clinical Research Center for Cancer.

In particular, the drug candidate BNT327/PM8002 developed by Biotheus will be a key area of focus after the deal closes.